You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物(06185.HK)擬將H股所得款項部分轉為在研疫苗開發及收購相關資產
阿思達克 08-24 09:45
康希諾生物(06185.HK)公布,截至今年6月30日,公司首次公開發售所得款項中約6.83億元人民幣(下同)仍然尚未使用。公司決議建議更改仍然尚未使用的首次公開發售所得款項的用途。

公司建議,原計劃用於在研MCV的研發及商業化的4.2億元未使用所得款項之建議分配,擬轉為用於先進技術、在研疫苗及生物製品的合作、許可及引入;在研疫苗的開發;及收購與疫苗及生物製品相關的優質資產。

公司指,於今年8月13日,公司已完成發行A股,並於上交所科創板上市。考慮本次A股發行獲得的募集資金淨額,連同與Pfizer的市場合作及公司的營運需要,為加強公司的資金使用效率,建議將原本分配作在研MCV商業化的部分尚未使用首次公開發售所得款項重新分配。公司在研MCV的商業化將以自A股發行獲得的超募資金撥支。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account